The contract from BARDA (75A50120C00180) will fund an upcoming Phase I clinical validation study designed to evaluate HD-MAP for pandemic influenza in 420 people, using both unadjuvanted and adjuvanted vaccine formulations. However, Vaxxas is also actively investigating opportunities to apply HD-MAP toward improving the performance of vaccines for other pandemics—including against COVID-19 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge